Oprozomib

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameOprozomib
Drug Alias NameOprozomib - Onyx Pharmaceuticals奥洛佐米奥泼佐米奥普佐米PR-047 +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProteasome inhibitorsApoptosis stimulants
TargetsProteasome
Therapy Area/IndicationsSolid tumoursNervous System NeoplasmsWaldenstrom Macroglobulinemia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen IncOno Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsSolid tumoursNervous System NeoplasmsWaldenstrom Macroglobulinemia +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG